09:46 AM EST - iCo Therapeutics : Reported the successful conclusion of pre-clinical studies involving its lead oral Amphotericin B candidate, including compelling safety data from its pivotal 14-day GLP (Good Laboratory Practices compliant) toxicology study. iCo Therapeutics
shares V.ICO are trading up $0.005 at $0.05.
